Status:
TERMINATED
Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Glaucoma
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successf...
Detailed Description
This is a randomized, open-label, Phase I/II study of intravitreally administered ranibizumab for the treatment of tube patency in glaucoma patients. Thirty (30) patients with severe glaucoma requiri...
Eligibility Criteria
Inclusion
- ability to provide written informed consent and comply with study assessment for the full duration of the study.
- age ≥ 21
- diagnosis of glaucoma and determined to be candidate for therapy with tube insertion.
Exclusion
- pregnant or lactating females
- Persons on oral contraceptives and women of child-bearing age
- prior enrollment in the study
- any conditions the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- participation in another simultaneous medical investigation or trial
- history of active inflammatory, infectious, or idiopathic keratitis precluding view of anterior segment structures
- previous injections of ranibizumab in either eye.
- Persons on Plavix (clopidogrel bisulfate) and coumadin
- Persons with uncontrolled high blood pressure
- Persons with renal or liver disease
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00644280
Start Date
April 1 2008
End Date
January 1 2011
Last Update
August 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143-0730